Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis

  • Espino-Paisan, Laura
  • Agudo-Jiménez, Teresa
  • Rosales-Martínez, Isabel
  • López-Cotarelo, Pilar
  • García-Martínez, María Ángel
  • Domínguez-Mozo, María Inmaculada
  • Pérez-Pérez, Silvia
  • Dieli-Crimi, Romina|||0000-0003-3413-5133
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Urcelay, Elena|||0000-0001-8470-8396
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
Myelin basic protein (MBP) is thought to be one of the key autoantigens in multiple sclerosis (MS) development. A recent study described the association of the single nucleotide polymorphism (SNP) rs12959006, within the MBP gene, with a higher risk of relapse and worse prognosis. We aim at studying potential associations of this SNP to MS in an independent population. Clinical data of the first 5 years of the disease were collected retrospectively from 291 MS confirmed patients. MBP polymorphism rs12959006 was genotyped in all patients. Associations with EDSS, number of relapses and serology for Herpesvirus 6 (HHV-6) and Epstein Barr (EBV) viruses were studied. Lymphocyte activation measured by CD69 expression was also analyzed according to sex and rs12959006 genotype. The rs12959006 polymorphism contributed significantly to a higher number of relapses at 5 years after onset only in male patients (rs12959006 ∗ TT β = 0.74 [0.36-1.09]; p = 7 × 10 -5). Titers of anti-HHV6 IgG antibodies showed also a mild association with relapses, both in male and female patients (β = 0.01 [0.01-0.02]; p = 3.7 × 10 -8). Both the genetic variation in MBP and HHV-6 infection aid in predicting a higher number of relapses during the first years of MS. The association described in MBP rs12959006 ∗ T is exclusive to male patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

  • Walo-Delgado, Paulette Esperanza
  • Monreal, Enric|||0000-0003-3293-0125
  • Medina, Silvia|||0000-0002-6051-173X
  • Quintana, Ester|||0000-0001-8885-1931
  • Sainz de la Maza, Susana|||0000-0001-8605-0049
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Lapuente, Paloma
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Montalban, Xavier|||0000-0002-0098-9918
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Villarrubia, Noelia
  • Carrasco-Sayalero, Angela
  • Rodríguez-Martín, Eulalia
  • Roldán, Ernesto
  • Meca-Lallana, Jose Eustasio|||0000-0001-5050-9890
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M|||0000-0002-9067-3668
UDHEBRON, To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.​